Song Sirong, Wu Haiyang, Wang Fanchen, Jiao Jiji, Xu Lixia, Wang Hongguang, Tong Xiaoguang, Yan Hua
Clinical College of Neurology, Neurosurgery and Neurorehabilitation, Tianjin Medical University, Tianjin, China.
Tianjin Neurosurgical Institute, Tianjin Key Laboratory of Cerebrovascular and Neurodegenerative Diseases, Tianjin Huanhu Hospital, Tianjin, China.
Front Oncol. 2022 Sep 29;12:926025. doi: 10.3389/fonc.2022.926025. eCollection 2022.
BACKGROUND: Glioma stem cells (GSCs) are a sub-population of cancer stem cells with capacity of self-renewal and differentiation. Accumulated evidence has revealed that GSCs were shown to contribute to gliomagenesis, distant metastasis as well as the resistance to radiotherapy and chemotherapy. As a result, GSCs were regarded as a promising therapeutic target in human glioma. The purpose of our study is to identify current state and hotspots of GSCs research by analyzing scientific publications through bibliometric methods. METHODS: All relevant publications on GSCs during 2003-2021 were extracted from the Science Citation Index Expanded of Web of Science Core Collection (WoSCC), and related information was collected and analyzed using Microsoft Excel 2016, GraphPad Prism 8 and VOSviewer software. RESULTS: A total of 4990 papers were included. The United States accounted for the largest number of publications (1852), the second average citations per item (ACI) value (67.54) as well as the highest H-index (157). was the most influential journal in this field. The most contributive institution was League of European Research Universities. RICH JN was the author with the most publications (109) and the highest H-index (59). All studies were clustered into 3 groups: "glioma stem cell properties", "cell biological properties" and "oncology therapy". The keywords "identification", "CD133" and "side population" appeared earlier with the smaller average appearing years (AAY), and the keywords"radiotherapy" and "chemotherapy" had the latest AAY. The analysis of top cited articles showed that "temozolomide", "epithelial-mesenchymal transition", and "immunotherapy" emerged as new focused issues. CONCLUSION: There has been a growing number of researches on GSCs. The United States has always been a leading player in this domain. In general, the research focus has gradually shifted from basic cellular biology to the solutions of clinical concerns. "Temozolomide resistance", "epithelial-mesenchymal transition", and "immunotherapy" should be given more attention in the future.
背景:胶质瘤干细胞(GSCs)是具有自我更新和分化能力的癌症干细胞亚群。越来越多的证据表明,GSCs在胶质瘤发生、远处转移以及对放疗和化疗的抗性中发挥作用。因此,GSCs被视为人类胶质瘤中一个有前景的治疗靶点。我们研究的目的是通过文献计量学方法分析科学出版物,以确定GSCs研究的现状和热点。 方法:从科学引文索引扩展版的Web of Science核心合集(WoSCC)中提取2003年至2021年期间所有关于GSCs的相关出版物,并使用Microsoft Excel 2016、GraphPad Prism 8和VOSviewer软件收集和分析相关信息。 结果:共纳入4990篇论文。美国的出版物数量最多(1852篇),其次是每项平均被引次数(ACI)值(67.54)以及最高H指数(157)。[此处原文可能缺失具体期刊名称]是该领域最具影响力的期刊。贡献最大的机构是欧洲研究型大学联盟。RICH JN是发表论文最多(109篇)且H指数最高(59)的作者。所有研究分为3组:“胶质瘤干细胞特性”、“细胞生物学特性”和“肿瘤治疗”。关键词“鉴定”、“CD133”和“侧群”出现较早,平均出现年份(AAY)较小,而关键词“放疗”和“化疗”的AAY最晚。高被引文章分析表明,“替莫唑胺”、“上皮-间质转化”和“免疫治疗”成为新的关注焦点。 结论:关于GSCs的研究越来越多。美国一直是该领域的领先者。总体而言,研究重点已逐渐从基础细胞生物学转向临床问题的解决。未来应更多关注“替莫唑胺抗性”、“上皮-间质转化”和“免疫治疗”。
Front Oncol. 2022-9-29
Medicine (Baltimore). 2024-5-17
Front Pharmacol. 2021-4-22
Front Bioeng Biotechnol. 2022-9-9
J Cent Nerv Syst Dis. 2024-10-16
Ann Surg Oncol. 2025-5
Quant Imaging Med Surg. 2024-12-5
Medicine (Baltimore). 2024-5-17
Front Mol Biosci. 2023-12-4
Front Pharmacol. 2021-4-22
Arch Osteoporos. 2021-4-17
Nat Commun. 2021-4-12
Environ Res. 2021-6
Stem Cell Res Ther. 2020-11-25